September 2, 2020Open Access

Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine

Key Points

Key points are not available for this paper at this time.

Abstract

At 35 days, NVX-CoV2373 appeared to be safe, and it elicited immune responses that exceeded levels in Covid-19 convalescent serum. The Matrix-M1 adjuvant induced CD4+ T-cell responses that were biased toward a Th1 phenotype. (Funded by the Coalition for Epidemic Preparedness Innovations; ClinicalTrials.gov number, NCT04368988).

Read Full Paperexternally

Demander à l'IA

Bookmark

View Full Paper

Cite This Study

Keech et al. (Wed,) studied this question.

synapsesocial.com/papers/69d777085f9a1dad5349049b https://doi.org/https://doi.org/10.1056/nejmoa2026920

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1The spike protein of SARS-CoV — a target for vaccine and therapeutic development2009 · 1,773 citations
2Matrix-M™ Adjuvant Induces Local Recruitment, Activation and Maturation of Central Immune Cells in Absence of Antigen2012 · 129 citations
3Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation2020 · 9,789 citations
4Effect of palivizumab prophylaxis in decreasing respiratory syncytial virus hospitalizations in premature infants2003 · 145 citations
5Improved Titers against Influenza Drift Variants with a Nanoparticle Vaccine2018 · 53 citations

Demander à l'IA

Bookmark

View Full Paper